Akcea Announces Completion of Landmark Study to Assess Disease Burden in People Living with FCS
Results published in Expert Review of Cardiovascular Therapy
Twenty-two people with FCS participated in the Re-FOCUS survey. They were asked to assess the number and severity of a range of symptoms and daily life measures affected by FCS. The web-based global study was conducted among people with FCS treated with volanesorsen, Akcea's investigational therapy currently under regulatory review in the US, EU and Canada.
"FCS is an ultra-rare disease that has not been widely studied. This landmark study represents an important step in our efforts to identify and quantify the many ways that FCS can affect the physical, functional and emotional health of people living with FCS," said Michael W. Stevenson, R.Ph., Ph.D., global vice president, medical affairs at Akcea. "The Re-FOCUS study provides helpful, new information as we work to design and validate a tool that can accurately evaluate changes in disease burden with therapeutic intervention."
The Re-FOCUS study represents another milestone in Akcea's ongoing efforts to understand the impact of FCS. In October 2017, Akcea announced results of the IN-FOCUS study, a survey of 166 people with FCS in 10 countries. The data provided new insight on the disease burden, including cognitive, emotional, and physical impairments that can affect daily life as well as the risk of recurrent, potentially fatal, acute pancreatitis.
"For people living with FCS, it impacts every part of daily life, often making it difficult to work, care for other family members or even join in life events with family and friends. Studies like IN-FOCUS and Re-FOCUS can enable patients and caregivers around the world to better understand and communicate about the devastating effects of this rare disease," said Lindsey Sutton, co-president of the FCS Foundation.
"We are working to increase understanding of FCS, through our clinical programs, scientific communications, and by bringing forward the voices of those who live with this disease," said Molly Harper, vice president, and global franchise head, cardiometabolics. "We would like to thank the FCS Foundation as well as all of the patients, caregivers and clinicians who participated in or supported this groundbreaking work, which will help build awareness and improve quality of care for patients with FCS and potentially other rare diseases."
FCS is an ultra-rare disease caused by impaired function of the enzyme lipoprotein lipase (LPL) and characterized by severe hypertriglyceridemia (>880mg/dL) and a risk of unpredictable and potentially fatal acute pancreatitis. Because of limited LPL function, people with FCS cannot breakdown chylomicrons, lipoprotein particles that are 90% triglycerides. In addition to pancreatitis, FCS patients are at risk of chronic complications due to permanent organ damage. They can experience daily symptoms including abdominal pain, generalized fatigue and impaired cognitions that affect their ability to work. People with FCS also report major emotional and psychosocial effects including anxiety, social withdrawal, depression and brain fog. There is no effective therapy for FCS currently available. Additional information on FCS is available at www.fcsfocus.com, and through the FCS Foundation at http://www.livingwithfcs.org and the LPLD Alliance at www.lpldalliance.org. For a full list of organizations supporting the FCS community worldwide, please click here.
ABOUT AKCEA THERAPEUTICS, INC.
Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), is a biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious and rare diseases. Akcea is advancing a mature pipeline of six novel drugs, including TEGSEDITM (inotersen), WAYLIVRATM (volanesorsen), AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, AKCEA-APOCIII-LRx, and AKCEA-TTR-LRx, all with the potential to treat multiple diseases. All six drugs were discovered by and are being co-developed with Ionis, a leader in antisense therapeutics, and are based on Ionis' proprietary antisense technology. TEGSEDI is under regulatory review in the U.S., EU and Canada for the treatment of people with hereditary transthyretin amyloidosis (hATTR). WAYLIVRA is under regulatory review in the U.S., EU and Canada for the treatment of familial chylomicronemia syndrome, or FCS, and is currently in Phase 3 clinical development for the treatment of people with familial partial lipodystrophy, or FPL. Akcea is building the infrastructure to commercialize its drugs globally. Akcea is a global company headquartered in Cambridge, Massachusetts. Additional information about Akcea is available at www.akceatx.com.
Forward Looking Statement
This press release includes forward-looking statements regarding the business of Akcea Therapeutics, Inc., and the therapeutic and commercial potential of WAYLIVRATM (volanesorsen) and other products in development. Any statement describing Akcea's goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. Akcea's forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Akcea's forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Akcea. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Akcea's programs are described in additional detail in its annual report on Form 10-K for the year ended December 31, 2017, which is on file with the SEC.
In this press release, unless the context requires otherwise, "Ionis," "Akcea," "Company," "Companies," "we," "our," and "us" refers to Ionis Pharmaceuticals and/or Akcea Therapeutics.
Ionis Pharmaceuticals(TM) is a trademark of Ionis Pharmaceuticals, Inc. Akcea Therapeutics(TM), TEGSEDITM and WAYLIVRATM are trademarks of Akcea Therapeutics, Inc.
Akcea Media and Investor Contact:
Head of Communications and Investor Relations
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Akcea Therapeutics, Inc. via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Talend Fall ’18 Enables Enterprises to Deliver Insight-Ready Data at Scale16.10.2018 10:15 | Pressemelding
Major integration platform update adds advanced catalog and API development capabilities and dramatically accelerates machine learning at scale REDWOOD CITY, Calif. and LONDON, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Talend (NASDAQ: TLND), a global leader in cloud data integration solutions, today announced a major update to Talend Data Fabric, the company’s unified data platform for data integration across complex, multi-cloud and on-premises environments. Announced at Talend Connect UK, Talend’s Fall 2018 release delivers insight-ready data at scale with new features including Data Catalog, which creates a single source of trusted data, and Cloud Application Programming Interface (API) Services, which speeds access to standardized data for building data-as-a-service applications and increasing productivity. Talend’s new release also accelerates running machine learning algorithms at scale with extended serverless big data support. “Data is at the heart of digital transformation, yet the pr
SAP® IT to Present on Agile Testing at SAP® TechEd® Barcelona Conference16.10.2018 08:00 | Pressemelding
Comprehensive Test Automation Strategy at Play Using SAP® CBTA and Worksoft Certify Dallas, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Worksoft ®, an SAP Silver Partner and leading global provider of continuous robotic test & process automation software for mission-critical enterprise applications, today announced that Worksoft Customer, SAP IT, will present at SAP® TechEd® annual conference being held October 23rd–25th in Barcelona, Spain. SAP IT’s featured conference demo session, “Agile Testing at SAP IT: Comprehensive Test Automation Strategy at Play,” will be held on Tuesday, October 23rd, at 15:00 CEST. Manuel Hermoso Martinez, SAP IT’s Information Technology Application Senior Consultant, will share how the organization successfully drives digital transformation with their Agile testing strategy. Manuel will offer best practices for embracing Agile to achieve end-to-end automation with SAP® CBTA and Worksoft Certify. During the afternoon speaking engagement, SAP will review their strateg
LeddarTech Expands its Engineering Expertise and Accelerates its Design Roadmap to Meet Market Demand16.10.2018 07:00 | Pressemelding
LeddarTech accelerates the development of its automotive LiDAR development platform, through organizational enhancements and the investment in two new engineering facilities in Toronto, Canada, and in Linz, Austria. QUEBEC CITY, Oct. 16, 2018 (GLOBE NEWSWIRE) -- LeddarTech, which develops a high-performance, cost-efficient solid-state LiDAR development platform for the automotive industry, is pleased to announce that it has greatly increased its automotive and semiconductor expertise through the hiring of two groups of world-class engineers to complement the existing engineering division. The company has recently expanded its operations to accommodate this growth in its new research and development office in Linz, Austria, as well as in its new Automotive Center of Excellence in Toronto, Canada. This key expansion brings to the Linz research and development office highly specialized engineering resources focused in microelectronic activities in support of the company’s LeddarCore syste
Vicor Introduces 10kW Power Tablet™ AC-DC Converter16.10.2018 03:00 | Pressemelding
Power Tablet RFM Enables High-Density Server Racks BEIJING, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Vicor Corporation (NASDAQ: VICR) has announced a 3-phase, AC-DC converter module (“RFM”), capable of delivering 10kW of regulated 48VDC in a power tablet configuration measuring 9.4 x 5.9 x 0.6in (24 x 15 x 1.5cm). The RFM™ provides a power-factor-corrected, regulated, and isolated DC output with integrated filtering and built-in fault protection for redundant operation. The RFM can be configured to accept worldwide 3-phase AC mains from 200 to 480VAC. The low-profile power tablet design of the RFM enables unprecedented power density and thermal management flexibility. For example, four RFMs in parallel, including input-disconnect circuitry, rectification and hold-up energy storage at 48V, can supply 40kW of power within 1U of rack space. The RFM power tablet package provides adept thermal management for advanced cooling, including liquid cooling, of high-power server racks for demanding HPC a
Elite Petro & Gas, a new brand by Elite Capital & Co. Limited15.10.2018 16:15 | Pressemelding
LONDON, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Today at Elite Petro & Gas headquarters in the City of London, Dr. Faisal Khazaal (Chairman) and Mr. George Matharu (President) announced the official launch of this new Division within Elite Capital & Co. Limited, which was setup to provide Finance, Trading and Advisory services in the global Oil and Gas markets. “Elite Petro & Gas is a Finance, Trading and Advisory firm with a focus on downstream activities in the global Oil and Gas markets. We are a results-driven business, working closely with our clients to deliver tangible solutions and outcomes.” Mr. George Matharu, President of Elite Petro & Gas, said. The oil and gas industry is facing challenging times, particularly from changes in the political landscape and increased price volatility. Understanding the nuances of working internationally, often in emerging economies and less stable regimes, is key to ensuring that business risks are appropriately managed. The Elite Petro & Gas (“EPG”
Prof. Dr. C. Oliver Kappe is awarded the 2018 IUPAC-ThalesNano Prize for Flow Chemistry15.10.2018 16:08 | Pressemelding
KARLSRUHE, Germany and BUDAPEST, Hungary and GRAZ, Austria, Oct. 15, 2018 (GLOBE NEWSWIRE) -- The 2018 IUPAC-ThalesNano prize has been awarded to Professor C. Oliver Kappe. The prize will be presented at the 15th International Conference on Microreaction Technology (IMRET15) in Karlsruhe on October 21, 2018. The award address will be delivered at the Flow Chemistry Europe Conference in Cambridge, UK on February 26th, 2019. The prize consists of an award of $10,000 US Dollars. Professor Kappe is Professor of Chemistry at the University of Graz (Austria) and Scientific Director for Continuous Flow Synthesis and Processing (CC Flow) at the Research Center Pharmaceutical Engineering GmbH (RCPE). Professor Kappe has over 400 publications in the areas of continuous flow chemistry, application of microreactors, process intensification, and microwave-assisted reactions. He and his team have published syntheses with challenging systems and chemistry. He has served as an Ambassador for Flow Chem
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom